Trump and Navarro press again for hydroxychloroquine. Can the FDA stay independent?

Jason Mast

Editor

Tuesday morning, economist and Trump advisor Peter Navarro walked onto the White House driveway and promptly brought a political cloud back onto the FDA. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Trump and Navarro press again for hydroxychloroquine. Can the FDA stay independent?

Jason Mast

Editor

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Bristol Myers CEO signals dealmaking will be a top priority in 2025

Drugmakers see a substantial, but manageable, hit to business from tariffs. But the worst may lie ahead

Roche CEO warns that tariffs could impact dealmaking

Roche takes steps to protect itself from tariffs, while Sanofi hangs back

Thermo Fisher buckles up for US-China trade war, budgets $2B to ease impact

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Trump and Navar­ro press again for hy­drox­y­chloro­quine. Can the FDA stay in­de­pen­dent?

Editor

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Trump and Navarro press again for hydroxychloroquine. Can the FDA stay independent?